
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc has demonstrated significant financial growth, reporting record total revenues of $12.1 million for the quarter, which is a 154% year-over-year increase and exceeds consensus estimates. The company's robust performance is attributed to an increase in the average selling price due to a higher volume of Medicare patients and a 106% year-over-year rise in total revenue units. Furthermore, with management anticipating total revenues to reach between $50 million and $53 million in 2025, along with a gross margin improvement to 71%, the company indicates strong operational momentum and a positive trajectory for future financial performance.
Bears say
Myomo Inc's reported backlog of insurance-authorized orders decreased to 272 from 316 in the previous quarter, indicating a potential decline in demand or sales pipeline. The company faces multiple significant risks including balance sheet and liquidity challenges, regulatory hurdles, and uncertainties surrounding product commercialization and reimbursement processes. Despite a net loss of $0.01 per share—slightly better than the consensus estimate—the overall sentiment remains negative due to these operational and market risks, weighing heavily on the company’s financial health and future prospects.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares